CBER outlines future biologics, biosimilars plans

With greater development of biologic medications, biosimilars and companion diagnostics, the FDA Center for Biologics Evaluation and Research's role in health care is growing, speakers said at FDLI's annual meeting. CBER office directors discussed plans for the center, which include a push to publish the draft guidance Preclinical Safety Assessment of Investigational Cellular and Gene Therapy Products.

View Full Article in:

CBER Importance Boosted With Attention To Biologic Drugs, Biosimilars, Speakers Say - Bloomberg BNA

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI